Fig. 4
From: Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis
Consensus molecular subtype (CMS) classification and gene set enrichment analysis (GSEA) hallmark pathways in patient-derived CRC-SCs. a Distribution of CMS groups in patient-derived CRC-SCs overexpressing SMYD3 (high-SMYD3) (n = 7) and not overexpressing SMYD3 (low-SMYD3) (n = 7). b GSEA results of the hallmark pathway in EM127-treated (5 μM for 24 h) vs untreated patient-derived CRC-SCs. The graphs represent the main hallmarks (y-axis) identified as significantly enriched in the high-SMYD3 and low-SMYD3 groups. The false discovery rate (FDR) Q value is also reported. c, d Dot plots of the top 20 ranked terms obtained from the Gene Ontology (GO) enrichment analysis (c) and the REACTOME analysis (d) of the MYC TARGETS V1 hallmark per the GSEA described in b. “Count” indicates the number of genes enriched in a GO term. “Gene ratio” indicates the percentage of enriched genes in the given GO term. e CancerMine (http://bionlp.bcgsc.ca/cancermine) classification of the c-MYC-downregulated and -upregulated targets identified as oncogenes (blue rectangles) or tumor suppressors (orange rectangle) in CRC
